Last reviewed · How we verify
ABP-745
At a glance
| Generic name | ABP-745 |
|---|---|
| Sponsor | Atom Therapeutics Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis (PHASE2)
- Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare (PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP-745 CI brief — competitive landscape report
- ABP-745 updates RSS · CI watch RSS
- Atom Therapeutics Co., Ltd portfolio CI